GeneDx Holdings Corp. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
GeneDx Holdings Corp. (WGS) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $23.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-23
- GeneDx Holdings Corp. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2022-06-30 was -$48.60M.
- GeneDx Holdings Corp. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $23.00M, a 3185.71% increase from fiscal 2024.
- GeneDx Holdings Corp. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $700.00K, a 98.44% decline from fiscal 2023.
- GeneDx Holdings Corp. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $44.90M, a 36.76% decline from fiscal 2022.
- GeneDx Holdings Corp. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $71.00M, a 27.10% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|---|
| 2025-12-31 | $23.00M 10-K · filed 2026-02-23 | ||
| 2024-12-31 | $700.00K 10-K · filed 2026-02-23 | ||
| 2023-12-31 | $44.90M 10-K · filed 2025-02-20 | ||
| 2022-12-31 | $71.00M 10-K · filed 2024-02-23 | ||
| 2022-06-30 | -$48.60M 10-Q · filed 2022-11-14 | ||
| 2021-12-31 | $97.40M 10-K · filed 2023-03-16 | ||
| 2020-12-31 | $40.37K 10-K/A · filed 2021-05-05 | $38.10M 10-K · filed 2023-03-16 | |
| 2019-12-31 | $7.10M 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |